BANK VONTOBEL/CALL/MODERNA/120/1/21.06.24 | Market Closed - Euronext Paris 17:30:01 14/06/2024 BST | ||
| 1.85 EUR | -24.80% |
|
| Current month | -10.22% | ||
| 1 month | +54.20% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 2.02 | -17.89% |
| 13/06/24 | 2.46 | -6.82% |
| 12/06/24 | 2.64 | -2.22% |
| 11/06/24 | 2.7 | +3.45% |
| 10/06/24 | 2.61 | -15.53% |
Real-time Euronext Paris
Last update June 14, 2024 at 05:30 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| JU94V | |
| ISIN | DE000VM2XWU8 |
| Date issued | 03/10/2023 |
| Strike | 120 $ |
| Maturity | 21/06/2024 (6 Days) |
| Parity | 1 : 1 |
| Emission price | 1.31 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.69 € |
|---|---|
| Lowest since issue | 0.265 € |
| Spread | 0.02 € |
| Spread % | 1.08% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
140
USD
Average target price
145.2
USD
Spread / Average Target
+3.67%
- Stock Market
- Warrants
- JU94V Warrant